Spinal muscular atrophy (SMA) is a rare genetic disorder that causes severe muscle weakness. SMA usually affects children, and is typically diagnosed in the first 18 months of life. In its most ...

Team Weimer recently consolidated its lab footprint to reside completely in the Engineering Center of the University of Colorado Boulder. We have cutting edge analytical equipment, and we are known ...

Ali Hussain has a background that consists of a career in finance with large financial institutions and in journalism covering business. Katrina Ávila Munichiello is an experienced editor, writer ...

Most people follow a prescribed outlook on life. However, University of North Georgia (UNG) student Erin Weimer is not most people. As Gender and Sexuality Alliance (GSA) president, Weimer aspires to ...

Scholar Rock Holding Corporation (NASDAQ:SRRK) just reported positive results from its phase 3 SAPPHIRE study using apitegromab for the treatment of patients with spinal muscular atrophy [SMA].

“We believe Archer will be a key partner as our SMA model business continues to gain momentum and we look to broaden our product offerings and onboard additional investment strategies throughout ...

A phase 3 trial of Scholar Rock’s spinal muscular atrophy (SMA) candidate has hit its primary endpoint, sparking a 200%-plus premarket surge in the biotech’s stock price. Investors went wild ...

Mr. Weimar began his education at RIT as a photography major but made the switch to the Professional and Technical Communications program to better his chances of working in advertising. He quickly ...

Driven by these trends, the KO stock broke above its 50-day simple moving average (SMA) yesterday, indicating the possibility of an uptrend ahead. On Monday, Coca-Cola closed trade at $70.34 ...

Gold price finds footing again above 21-day SMA at $2,627, more recovery likely? Gold price is looking to build on the previous recovery from three-week lows of $2,604 early Friday. Broad risk ...

His confidence stems from the positive results of the SAPPHIRE trial for the treatment of SMA (Spinal Muscular Atrophy) with T-Alfa, a myostatin inhibitor. Shrader perceives the drug’s dual ...

for patients with SMA receiving apitegromab versus placebo (current standard of care) at week 52 30.4% of patients receiving apitegromab had >3 point improvement in HFMSE versus 12.5% of patients ...